- Query in any language with multilingual search
- Access EUR-Lex and EU Commission case law
- See relevant paragraphs highlighted instantly
Similar Documents
Explore similar documents to your case.We Found Similar Cases for You
Case T-12/24: Action brought on 10 January 2024 — Ferring Pharmaceuticals v Commission
ECLI:EU:UNKNOWN:62024TN0012
62024TN0012
With us you find everything. Try it now!
I imagine what I want to write in my case, I write it in the search engine and I get exactly what I wanted. Thank you!
Valentina R., lawyer
Official Journal of the European Union
EN
Series C
C/2024/2167
25.3.2024
(Case T-12/24)
(C/2024/2167)
Language of the case: English
Parties
Applicant: Ferring Pharmaceuticals A/S (Kastrup, Denmark) (represented by: F. Pochart and E. Mignon, lawyers)
Defendant: European Commission
Form of order sought
The applicant claims that the Court should:
—declare the application for annulment admissible and well-founded;
—annul Commission Implementing Decision C(2023) 6669 final of 29 September 2023 granting marketing authorisation under Regulation (EC) No 726/2004 of the European Parliament and of the Council (1) for ‘Degarelix Accord — degarelix acetate’, a medicinal product for human use, in its entirety (OJ C/2023/298);
—order the Commission to bear the costs of the proceedings.
Pleas in law and main arguments
In support of the action, the applicant relies on two pleas in law.
1.First plea in law, alleging that the European Commission committed a violation of essential procedural requirements by deviating from the European guidelines on bioequivalence without justification and by relying on a draft foreign guideline instead.
2.Second plea in law, alleging that the European Commission committed a manifest error of assessment by allowing the applicant to the generic medicinal product not to provide the necessary bioequivalence studies.
*
(1) Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency (OJ 2004, L 136, p. 1).
ELI: http://data.europa.eu/eli/C/2024/2167/oj
ISSN 1977-091X (electronic edition)